Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension - Grünig, Ekkehard; Jansa, Pavel; Fan, Fenling; Hauser, Jakob A.; Pannaux, Matthieu; Morganti, Adele; Rofael, Hany; Chin, Kelly M. (Journal of the American College of Cardiology, 2024)
Keywords: Cardiovascular; Combined Modality Therapy; Endothelin Receptor Antagonists; Humans; macitentan; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Pyrimidines; randomized controlled trial; single-tablet (fixed-dose) combination therapy; Sulfonamides; Tablets; Tadalafil; PDE5i; tadalafil; AE; CL; single-tablet (fixed-dose) combination therapy; PVR; randomized controlled trial; WHO FC; NT-proBNP; macitentan; ERA; M/T FDC; PAH; pulmonary arterial hypertension; 6MWD; World Health Organization functional class; adverse event; 6-minute walk distance; confidence limit; phosphodiesterase 5 inhibitor; macitentan and tadalafil fixed-dose combination; endothelin receptor antagonist; pulmonary vascular resistance; N-terminal pro-brain natriuretic peptide